Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/62213

TitleTrends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems
Author(s)Souto, Eliana
Dias-Ferreira, João
Oliveira, Jéssica
Sanchez-Lopez, Elena
Lopez-Machado, Ana
Espina, Marta
Garcia, Maria L.
Souto, Selma B.
Martins-Gomes, Carlos
Silva, Amélia M.
Keywordsatopic dermatitis
drug delivery systems
pharmacological treatment
nanotechnology
nanoparticles
Issue date12-Nov-2019
PublisherMDPI
JournalInternational Journal of Molecular Sciences
CitationSouto, Eliana; Dias-Ferreira, João; Oliveira, Jéssica; Sanchez-Lopez, Elena; Lopez-Machado, Ana; Espina, Marta; Garcia, Maria L.; Souto, Selma B.; Martins-Gomes, Carlos; Silva, Amélia M., Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems. International Journal of Molecular Sciences, 20(22), 5659, 2019
Abstract(s)Atopic dermatitis (AD) is a predominant and deteriorating chronic inflammation of the skin, categorized by robust burning and eczematous lacerations in diverse portions of the body. AD affects about 20% of both offspring and adults worldwide. The pathophysiology of AD combines environmental, hereditary, and immunological aspects, together with skin barrier dysfunction. The procedures used to prevent the disease are the everyday usage of creams to support the restoration of the epidermal barrier. The classical treatments include the use of topical corticosteroids as a first-line therapy, but also calcineurin inhibitors, antihistamines, antibiotics, phototherapy, and also immunosuppressant drugs in severe cases of AD. Topical drug delivery to deeper skin layers is a difficult task due to the skin anatomic barrier, which limits deeper penetration of drugs. Groundbreaking drug delivery systems, based on nanoparticles (NPs), have received much attention due to their ability to improve solubility, bioavailability, diffusion, targeting to specific types of cells, and limiting the secondary effects of the drugs employed in the treatment of AD. Even so, additional studies are still required to recognize the toxicological characteristics and long-term safety of NPs. This review discusses the current classical pharmacotherapy of AD against new nanoparticle skin delivery systems and their toxicologic risks.
TypeArticle
URIhttp://hdl.handle.net/1822/62213
ISBN1424-6783
DOI10.3390/ijms20225659
ISSN1422-0067
e-ISSN1661-6596
Publisher versionhttp://www.mdpi.com/journal/ijms
Peer-Reviewedyes
AccessOpen access
Appears in Collections:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Files in This Item:
File Description SizeFormat 
document_52187_1.pdf1,23 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID